Merck's Ebola Vaccine Will Get US FDA Decision Before March Review Deadline
Staffer says agency will make a licensure decision "well ahead" of the March action date; 230,000 have received the vaccine under compassionate use.
You may also be interested in...
The latest news on novel drug approvals and complete response letters from our US FDA Performance Tracker.
Merck Sharp & Dohme will begin manufacturing licensed doses of Ervebo in Germany and will continue to send investigational vaccine doses to Democratic Republic of Congo.
The latest drug development news and highlights from our US FDA Performance Tracker include a Neulasta biosimilar approval for Sandoz, novel approvals for Celgene's Reblozyl and Giskit B.V.'s ExEm Foam, and a submission for Regeneron's Ebola candidate.